SAN FRANCISCO, Sept. 25, 2019 /PRNewswire/ — Agathos is pleased to announce its partnership with Erlanger Health System and MDP Management, a Chattanooga-based hospitalist group, to help manage practice variation. With leadership from David Alvarez MD and the rest of the MDP team, Agathos helps Erlanger scale the “last mile” of physician engagement toward valuable care. Erlanger Health System is a nationally acclaimed, multi-hospital health system treating more than 600,000 people annually:
After supporting MDP hospitalists at Erlanger through numerous quality initiatives, Agathos looks forward to expanding the relationship to physicians in other acute care specialties, starting with emergency medicine.
“We are excited to work side-by-side with Erlanger’s attending physicians and support delivery of the highest quality, most compassionate care in the region,” said Andrew Trees, CEO of Agathos. “Erlanger Health System has long enjoyed exceptional clinician buy-in to quality improvement initiatives, and its leadership continues to commit to providing physicians the best, most cutting-edge technology in support of measurable clinical excellence.”
Agathos’ transparency platform leverages the following principles designed to put physicians at the helm of their own clinical autonomy while empowering teams to collaborate, learn, and improve together:
ABOUT AGATHOS
Agathos is the transparency platform, by physicians for physicians, giving superior feedback on practice variation— scaling the “last mile” of physician engagement toward valuable care. We partner with health systems—maximizing the benefits of technology investments already made—to empower each physician toward ever-higher quality, cost stewardship, and organizational alignment.
Media Contact:
Vladimir Tikhtman, Head of Marketing
Telephone: 312-497-5519
Email: 223505@email4pr.com
Website: https://www.agathos.io/
SOURCE Agathos
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…